STOCK TITAN

Annexon (NASDAQ: ANNX) Form 144 shows tiny 853-share insider sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Annexon, Inc. (NASDAQ: ANNX) filed a Form 144 disclosing a proposed insider sale of up to 853 common shares, valued at approximately $2,226.42. The shares, representing roughly 0.0008% of the 109.7 million shares outstanding, were acquired through restricted-stock vesting on 07 Jul 2025 and are slated for sale on or about 14 Jul 2025 via Fidelity Brokerage Services LLC on the NASDAQ exchange.

No other sales by the filer in the past three months were reported, and the filing contains the standard affirmation that the seller possesses no undisclosed material adverse information. Filer name and relationship to the issuer were not provided, suggesting an administrative notice rather than a significant ownership change.

Given the minimal share count and dollar value, this transaction is considered routine and unlikely to affect Annexon’s capital structure, liquidity, or share price. Investors typically view such small-scale Form 144 filings as non-material disclosures.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: 853-share Form 144 sale is negligible; no impact on ANNX investment thesis.

The filing covers less than one-thousandth of a percent of Annexon’s outstanding shares, valued at just over $2,200. There is no indication of broader insider selling pressure or strategic shift. Absence of the filer’s identity limits insight into motive, but the tiny size and origin from routine RSU vesting point to standard personal liquidity. I classify the disclosure as neutral and not impactful for equity valuation or trading dynamics.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Annexon’s (ANNX) latest Form 144 disclose?

It reveals an insider’s intent to sell 853 common shares valued at about $2,226.42.

How large is the planned sale relative to Annexon’s shares outstanding?

The 853 shares equal roughly 0.0008% of the company’s 109,714,404 shares outstanding.

When is the approximate sale date for the ANNX shares?

The shares are expected to be sold on or around 14 July 2025.

Which broker is handling the ANNX insider transaction?

The sale will be executed through Fidelity Brokerage Services LLC.

Were any other Annexon insider sales reported in the past three months?

No. The filer indicated "Nothing to Report" for prior three-month sales.
Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

ANNX Latest News

ANNX Latest SEC Filings

ANNX Stock Data

809.37M
134.16M
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE